Literature DB >> 11509595

Antigen-specific blockade of T cells in vivo using dimeric MHC peptide.

S M O'Herrin1, J E Slansky, Q Tang, M A Markiewicz, T F Gajewski, D M Pardoll, J P Schneck, J A Bluestone.   

Abstract

Ag-specific immune tolerance in clinical organ transplantation is currently an unrealized but critical goal of transplant biology. The specificity and avidity of multimerized MHC-peptide complexes suggests their potential ability to modulate T cell sensitization and effector functions. In this study, we examined the ability of MHC-peptide dimers to modulate T cell function both in vitro and in vivo. Soluble MHC dimers induced modulation of surface TCR expression and inhibited T cell cytolytic activity at nanomolar concentrations in vitro. Furthermore, engagement of TCR by soluble dimers resulted in phosphorylation of the TCR zeta-chain and recruitment and phosphorylation of zeta-associated protein-70 to the signaling complex, the latter of which increased upon dimer cross-linking. Significantly, Ag-specific inhibition of an alloreactive TCR-transgenic T cell population in vivo resulted in consequent outgrowth of an allogeneic tumor. The prolonged Ag-specific suppression of expansion and/or effector function of cognate T cells in vivo suggests that soluble MHC dimers may be a means of inducing sustained Ag-specific T cell unresponsiveness in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509595     DOI: 10.4049/jimmunol.167.5.2555

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

Review 1.  New therapeutic strategies targeting transmembrane signal transduction in the immune system.

Authors:  Alexander B Sigalov
Journal:  Cell Adh Migr       Date:  2010-04-24       Impact factor: 3.405

Review 2.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

Review 3.  Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?

Authors:  Xavier Clemente-Casares; Sue Tsai; Yang Yang; Pere Santamaria
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

4.  Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Authors:  Natalia Ramírez; Lorea Beloki; Miriam Ciaúrriz; Mercedes Rodríguez-Calvillo; David Escors; Cristina Mansilla; Eva Bandrés; Eduardo Olavarría
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

5.  The SCHOOL of nature: III. From mechanistic understanding to novel therapies.

Authors:  Alexander B Sigalov
Journal:  Self Nonself       Date:  2010-06-11

Review 6.  Surface engineering for lymphocyte programming.

Authors:  Elana Ben-Akiva; Randall A Meyer; David R Wilson; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2017-05-10       Impact factor: 15.470

Review 7.  Nanoengineering approaches to the design of artificial antigen-presenting cells.

Authors:  Joel C Sunshine; Jordan J Green
Journal:  Nanomedicine (Lond)       Date:  2013-07       Impact factor: 5.307

8.  In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Authors:  Stefano Ugel; Alessia Zoso; Carmela De Santo; Yu Li; Ilaria Marigo; Paola Zanovello; Elisa Scarselli; Barbara Cipriani; Mathias Oelke; Jonathan P Schneck; Vincenzo Bronte
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 9.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

Review 10.  Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.

Authors:  M Campoli; S Ferrone
Journal:  Tissue Antigens       Date:  2008-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.